Profil
Jaime Simon is the founder of IGL Pharma, Inc. where he holds the title of Director since 2016.
He is also the founder of IsoTherapeutics Group LLC, where he holds the title of Chief Scientific Officer & Vice President since 2005.
Aktive Positionen von Jaime Simon
| Unternehmen | Position | Beginn |
|---|---|---|
IGL Pharma, Inc.
 IGL Pharma, Inc. Medical/Nursing ServicesHealth Services IGL Pharma, Inc. provides health care services. The company was founded in 2016 by Keith R. Frank and Jamie Simon and is headquartered in Angleton, TX. | Gründer | 01.01.2016 |
IsoTherapeutics Group LLC
 IsoTherapeutics Group LLC BiotechnologyHealth Technology Part of Telix Pharmaceuticals Ltd., IsoTherapeutics Group LLC is a radiopharmaceutical company that offers technologies for developing novel therapeutic and diagnostic agents. The company is based in Angleton, TX. The company was founded in 2005 by Jaime Simon, Keith R. Frank. Keith R. Frank has been the CEO of the company since 2005. IsoTherapeutics Group was acquired by Telix Pharmaceuticals Ltd. on April 09, 2024 for $13.63 million. | Gründer | 01.01.2005 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
IGL Pharma, Inc.
IGL Pharma, Inc. Medical/Nursing ServicesHealth Services IGL Pharma, Inc. provides health care services. The company was founded in 2016 by Keith R. Frank and Jamie Simon and is headquartered in Angleton, TX. | Health Services |
IsoTherapeutics Group LLC
IsoTherapeutics Group LLC BiotechnologyHealth Technology Part of Telix Pharmaceuticals Ltd., IsoTherapeutics Group LLC is a radiopharmaceutical company that offers technologies for developing novel therapeutic and diagnostic agents. The company is based in Angleton, TX. The company was founded in 2005 by Jaime Simon, Keith R. Frank. Keith R. Frank has been the CEO of the company since 2005. IsoTherapeutics Group was acquired by Telix Pharmaceuticals Ltd. on April 09, 2024 for $13.63 million. | Health Technology |
